Regeneron (REGN) Still Undervalued Despite 20% Gain
Regeneron Pharmaceuticals (REGN) stock gained 20.2% over the past year, yet valuation metrics suggest it remains undervalued. Regulatory progress for cemdisiran and advances in obesity treatment support growth expectations.
Key Numbers
According to Simply Wall St., Regeneron Pharmaceuticals (REGN) stock has returned 20.2% over the past 12 months, putting recent investors in profit. However, current valuation checks still lean toward the shares looking inexpensive rather than stretched.
Recommendation Change
No explicit recommendation change was mentioned in the report, but the analysis indicates the stock is trading below its fair value based on valuation metrics.
Analyst Rationale
Analysts see regulatory momentum around treatments like cemdisiran (for kidney disease) and progress in the obesity treatment space as supporting growth expectations. These factors could justify a higher valuation.
Context
The stock's performance over the past year has been positive at 20.2%, but valuation remains attractive compared to peers. No other analyst opinions were provided in the report.
What to Make of It
While the stock has shown good gains, the question remains whether future catalysts will be sufficient to drive further upside. Investors are advised to monitor regulatory and clinical developments.
Frequently Asked Questions
Found this useful? Share it